We’ve continued to see more data released emphasizing the safety of biosimilar switching abroad. However, as Merck KGaA Darmstadt Germany's Sue Naeyaert argues, these data alone are unlikely to be the silver bullet to greater biosimilar uptake. In an interview, Naeyaert shared her thoughts about how interchangeability in the U.S. will play out, as well as how biosimilar use could be incentivized in the fragmented American healthcare system.
Edric Engert, managing director of Abraxeolus Consulting (formerly of Teva), shares his opinions on where the biosimilar market is heading, how we can promote greater uptake within the U.S., and just how “genericized” the market can and will potentially become.
This is the third article in a series on biosimilars. The first two pieces layout the background of the biosimilar market to date and the challenges shaping the market. This article sets out to explain how biosimilar companies are achieving differentiation and what it will take to establish market share.
Last year, after the fateful June 2016 Brexit referendum that ended in a shocking win for the “Leave” camp, I wrote an article discussing the options going forward and the uncertainty that faced the biopharmaceutical industry. Now, almost a year later and after the official triggering of Article 50 — through a letter delivered by Eurostar, no less — have we actually learned anything new?
In the pharmaceutical industry, five years is a short length of time in which to launch a company, establish a development process, and bring several biosimilar candidates to market. In an interview, Paul Song shared some of the efforts Samsung Bioepis has made to pass down lessons learned and to continue evolving in the years ahead.
President Trump promised to take action to streamline the federal government. Within just a few days of taking office, he launched his deregulatory agenda, and he has now issued several executive orders that build on each other. How the concept will be implemented and by whom will continue to evolve with the addition of key staff.
This article provides details of the different players that exist in the complex biosimilar market, all of which have different characteristics, histories, reasons for entry, internal capabilities and resources available to support their programs.
Given the contradictory atmosphere surrounding PBMs, how is one to know whether structural relief is needed or, on the contrary, if overregulation should be averted?
Based on a detailed review of the biosimilar market, it is clear that this market is highly dynamic. While the biosimilar market has not yet fully lived up to the initial expectations, it may be on the brink of considerable and rapid change.
Samsung Bioepis celebrated its fifth anniversary in February 2017. I met with Paul Song, VP at Samsung Bioepis, to learn more about the company's motto, "Process innovation," which is credited for the company's swift rise to leadership in the European market.
GE Healthcare has compiled this ebook, which includes information on some of the latest SUT trends in the world of bioprocessing.
New drugs acquired via mergers, acquisitions or licensing agreements often come with an entourage of contract manufacturers. After several such transactions, you can find yourself surrounded by a tangle of CMOs. That’s problematic. Complex CMO networks are expensive and require many resources to manage. Plus, they prevent purchasing and operating at scale. Yet, the process of consolidating CMOs is daunting. Where do you begin?
Immunotherapies are being touted—both in scientific literature and the general media—as the most promising advances in cancer treatment in decades.
This application note describes mixing and heating-cooling characterization data for the Xcellerex XDM/ XDUO 500 single-use mixer. A design of experiments (DoE) approach to liquid-liquid mixing was successfully applied to establish a statistical model to predict the mixing time throughout the working range.
This application note describes mixing and heating-cooling characterization data for the Xcellerex XDM/ XDUO 200 single-use mixer. A design of experiments (DoE) approach to liquid-liquid mixing was successfully applied to establish a model to predict the mixing time throughout the working range. Liquid-liquid mixing times as low as 13 s were observed at the nominal volume (200 L) and highest viscosity tested (20 cP).
Biosimilar Development is dedicated to presenting technical information, thought leadership, and commentary for the biosimilar development and manufacturing community. On this site, users will find exclusive and actionable content on the industry trends and challenges affecting the emerging biosimilars market. Browse our articles, case studies, and white papers on topics related to biosimilar development, manufacturing, quality, distribution, FDA guidance, BPCIA, global markets, government regulations, and intellectual property.
Biosimilar Development is part of the Life Science Connect media group, which strives to facilitate connections and foster collaborations in pharmaceutical development to find ways to get more life-saving and life-improving therapies to market. Connect, Collaborate, Contribute.